title: Edwards CENTERA valve.
abstract: Transcatheter aortic valve implantation (TAVI) has been adopted worldwide as a prominent therapeutic alternative for patients with high-risk severe symptomatic aortic stenosis. Despite its more widespread adoption as a treatment option and the increasing experience of the centres, TAVI is still associated with complications. Therefore, improvements in transcatheter heart valve (THV) technology, such as optimisation of device function with superior deliverability, and valve repositioning, are desirable. Accordingly, this article describes the new self-expandable Edwards CENTERA THV, made of nitinol and treated bovine pericardial tissue, and delivered by a motorised low-profile delivery system which potentially permits accurate valve placement and valve repositioning by a single operator. First-in-human clinical experience with the CENTERA THV has been promising but larger series with longer follow-up are warranted to confirm these initial positive results.
authors.affiliation: Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.
authors.forename: Henrique Barbosa
authors.initials: HB
authors.lastname: Ribeiro
authors.forename: Marina
authors.initials: M
authors.lastname: Urena
authors.forename: Karl-Heinz
authors.initials: KH
authors.lastname: Kuck
authors.forename: John G
authors.initials: JG
authors.lastname: Webb
authors.forename: Josep
authors.initials: J
authors.lastname: Rodés-Cabau
mesh_terms: D001024:Aortic Valve Stenosis / Q000503:physiopathology / Q000628:therapy*; D001705:Bioprosthesis; D006328:Cardiac Catheterization / Q000009:adverse effects / Q000295:instrumentation*; D019317:Evidence-Based Medicine; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods; D006439:Hemodynamics; D006801:Humans; D018579:Patient Selection; D011474:Prosthesis Design; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome